o
|
Transition Report on Form 10-K |
o | Transition Report on Form 20-F |
o | Transition Report on Form 11-K |
o | Transition Report on Form 10-Q |
o | Transition Report on Form N-SAR |
Full
Name of Registrant:
|
Sangui
Biotech International, Inc.
|
Former
Name if Applicable:
|
Not
Applicable
|
Address
of Principal Executive Office:
|
Alfred-Herrhausen-Str.
44, 58455, Witten, Germany
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense;
|
|
x
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will
be filed on or before the fifteenth calendar day following the prescribed
due date; or the subject quarterly report or transition report on Form
10-Q or subject distribution report on Form 10-D, or portion thereof, will
be filed on or before the fifth calendar day following the prescribed due
date; and
|
(c)
|
The
accountant's statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
Date:
|
February
13, 2008
|
/s/
Thomas Striepe
|
|
By:
|
Thomas
Striepe
President
and Chief Executive Officer
|